Enanta Pharmaceuticals Inc (NASDAQ: ENTA)’s stock price has increased by 5.87 compared to its previous closing price of 4.26. However, the company has seen a -4.65% decrease in its stock price over the last five trading sessions. businesswire.com reported 2025-04-08 that WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025.
Is It Worth Investing in Enanta Pharmaceuticals Inc (NASDAQ: ENTA) Right Now?
ENTA has 36-month beta value of 0.92. Analysts have mixed views on the stock, with 2 analysts rating it as a “buy,” 2 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for ENTA is 19.82M, and currently, short sellers hold a 13.46% ratio of that float. The average trading volume of ENTA on April 11, 2025 was 393.76K shares.
ENTA’s Market Performance
ENTA stock saw a decrease of -4.65% in the past week, with a monthly decline of -33.97% and a quarterly a decrease of -11.39%. The volatility ratio for the week is 12.21%, and the volatility levels for the last 30 days are 7.78% for Enanta Pharmaceuticals Inc (ENTA). The simple moving average for the last 20 days is -17.54% for ENTA stock, with a simple moving average of -52.57% for the last 200 days.
Analysts’ Opinion of ENTA
Many brokerage firms have already submitted their reports for ENTA stocks, with JP Morgan repeating the rating for ENTA by listing it as a “Underweight.” The predicted price for ENTA in the upcoming period, according to JP Morgan is $14 based on the research report published on August 09, 2023 of the previous year 2023.
Jefferies, on the other hand, stated in their research note that they expect to see ENTA reach a price target of $18, previously predicting the price at $49. The rating they have provided for ENTA stocks is “Hold” according to the report published on August 08th, 2023.
H.C. Wainwright gave a rating of “Buy” to ENTA, setting the target price at $56 in the report published on December 09th of the previous year.
ENTA Trading at -28.26% from the 50-Day Moving Average
After a stumble in the market that brought ENTA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -73.83% of loss for the given period.
Volatility was left at 7.78%, however, over the last 30 days, the volatility rate increased by 12.21%, as shares sank -31.88% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -11.87% lower at present.
During the last 5 trading sessions, ENTA fell by -4.23%, which changed the moving average for the period of 200-days by -63.02% in comparison to the 20-day moving average, which settled at $5.47. In addition, Enanta Pharmaceuticals Inc saw -21.57% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ENTA starting from Luly Jay R., who purchase 45,000 shares at the price of $5.69 back on Feb 12 ’25. After this action, Luly Jay R. now owns 846,638 shares of Enanta Pharmaceuticals Inc, valued at $256,050 using the latest closing price.
Kieffer Tara Lynn, the Chief Product Strategy Officer of Enanta Pharmaceuticals Inc, sale 2,283 shares at $8.06 during a trade that took place back on Dec 06 ’24, which means that Kieffer Tara Lynn is holding 29,305 shares at $18,401 based on the most recent closing price.
Stock Fundamentals for ENTA
Current profitability levels for the company are sitting at:
- -1.66 for the present operating margin
- 0.99 for the gross margin
The net margin for Enanta Pharmaceuticals Inc stands at -1.58. The total capital return value is set at -0.37. Equity return is now at value -69.10, with -27.00 for asset returns.
Based on Enanta Pharmaceuticals Inc (ENTA), the company’s capital structure generated 0.34 points at debt to capital in total, while cash flow to debt ratio is standing at -1.23. The debt to equity ratio resting at 0.51. The interest coverage ratio of the stock is -11.66.
Currently, EBITDA for the company is -104.51 million with net debt to EBITDA at 0.28. When we switch over and look at the enterprise to sales, we see a ratio of 1.04. The receivables turnover for the company is 1.66for trailing twelve months and the total asset turnover is 0.19. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.47.
Conclusion
To put it simply, Enanta Pharmaceuticals Inc (ENTA) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
